With $100M round, Cambrian tackles aging disorders via hub-and-spoke model

Cambrian believes its hub-and-spoke model will allow it to advance a diverse group of programs with one unifying theme: therapeutics that could also be developed as prophylactic interventions for aging-related disorders.

On Tuesday, an investor syndicate backed Cambrian Biopharma with $100 million in series C cash, building on $60 million in prior investments. Anthos Capital and SALT Fund were the series C leaders...